Certain site-directed, nonenzymatically active mutants of the Haemophilus influenzae P4 lipoprotein are able to elicit bactericidal antibodies.
The Haemophilus influenzae P4 lipoprotein (hel) is a potential component of a nontypeable H. influenzae otitis media vaccine. Since P4 is known to be an enzyme, nonenzymatically active forms of recombinant P4 are required. After site-directed mutagenesis of the hel gene, three of the mutated proteins were shown to be vaccine candidates.
Wyeth Vaccines Discovery Research, Bldg. 205/3104, 401 N. Middletown Road, Pearl River, New York 10965, USA. greenba@wyeth.com
Bruce A
BA
Green
Elizabeth
E
Baranyi
Thomas J
TJ
Reilly
Arnold L
AL
Smith
Gary W
GW
Zlotnick
D000907:Antibodies, Bacterial / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D008074:Lipoproteins / Q000276:immunology*; D009154:Mutation; D013329:Structure-Activity Relationship
D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D008074:Lipoproteins